Levomilnacipran Extended-Release Capsules Suppliers & Bulk Manufacturers
Available Forms: Extended-Release Capsules
Available Strengths: 20 mg, 40 mg, 80 mg, 120 mg
Reference Brands: Fetzima®(US)
Category:
Antipsychotropic Drugs
Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases levels of these neurotransmitters in the brain to improve mood and energy. It is used for the treatment of major depressive disorder (MDD) in adults. The extended-release formulation allows for once-daily dosing and provides consistent therapeutic levels throughout the day.
Levomilnacipran Extended-Release Capsules is available in Extended-Release Capsules
and strengths such as 20 mg, 40 mg, 80 mg, 120 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Levomilnacipran Extended-Release Capsules is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Levomilnacipran Extended-Release Capsules can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Levomilnacipran extended-release (ER) capsules are FDA-approved in the United States for the treatment of major depressive disorder (MDD) in adults. As a serotonin-norepinephrine reuptake inhibitor (SNRI), the ER formulation provides consistent plasma levels and once-daily dosing. U.S. regulations mandate boxed warnings for increased suicidal thoughts in young adults, GMP-compliant manufacturing, bioequivalence studies for generics, and post-marketing pharmacovigilance.
In the European Union, levomilnacipran is not widely marketed, but companies may pursue national or decentralized procedures for approval. EU requirements include a comprehensive Risk Management Plan (RMP), clinical safety and efficacy data, and robust pharmacovigilance measures. For dossier-ready sourcing, visit Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing